Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Allergan : to Report Third Quarter 2017 Earnings and Host Conference Call and Webcast

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 10:25am CET

Release date- 03102017 - DUBLIN - Allergan plc (NYSE: AGN) today announced it intends to release third quarter 2017 financial results on Wednesday, November 1, 2017, prior to the open of the U.S. Financial Markets.

Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, November 1, 2017 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 65879759.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion, and will remain available through 11:30 p.m. Eastern Time on December 1, 2017. The replay may be accessed by dialing (855) 859-2056 and entering the conference ID 65879759. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same conference ID.

To access the webcast, please visit Allergan's Investor Relations website at ttps://www.allergan.com/inves.... A replay of the webcast will also be available on Allergan's Investor Relations website.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan'scurrent perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDAapprovals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergandisclaims any intent or obligation to update these forward-looking statements.


Daphne Karydas

Tel: (862) 261-8006

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
12/17 TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
12/14 ALLERGAN : Receives FDA Clearance for the CoolSculpting Treatment to Improve App..
12/13 TEVA PHARMACEUTICAL INDUSTRIES : Fears of Israeli job cuts at Teva sparks call f..
12/12 ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/07 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
12/07 EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
11/30 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
More news
News from SeekingAlpha
12/15 Prospects dim for European approval of Repros' enclomiphene for secondary hyp..
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/14 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
12/13 Top 10 Net Payout Yields For December 2017
Financials ($)
Sales 2017 15 894 M
EBIT 2017 7 658 M
Net income 2017 -6 486 M
Debt 2017 24 765 M
Yield 2017 1,67%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,15x
EV / Sales 2018 5,11x
Capitalization 57 098 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 225 $
Spread / Average Target 31%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-18.25%57 098
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386